Short Interest in Orion Oyj (OTCMKTS:ORINY) Drops By 50.0%

Orion Oyj (OTCMKTS:ORINY) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 300 shares, a decrease of 50.0% from the February 28th total of 600 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 1,400 shares, the days-to-cover ratio is presently 0.2 days.

Orion Oyj Price Performance

OTCMKTS ORINY traded up $0.68 on Friday, hitting $29.35. The company had a trading volume of 680 shares, compared to its average volume of 3,220. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.42 and a quick ratio of 1.41. The company’s fifty day moving average price is $27.98 and its 200-day moving average price is $25.69. The company has a market capitalization of $8.28 billion, a PE ratio of 23.29 and a beta of 0.25. Orion Oyj has a 12-month low of $17.50 and a 12-month high of $30.57.

Orion Oyj (OTCMKTS:ORINY) last announced its earnings results on Tuesday, February 25th. The company reported $0.28 earnings per share (EPS) for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. The business had revenue of $463.41 million for the quarter. As a group, analysts predict that Orion Oyj will post 1.18 earnings per share for the current year.

Orion Oyj Increases Dividend

The company also recently disclosed a dividend, which will be paid on Tuesday, April 29th. Shareholders of record on Monday, April 7th will be paid a dividend of $0.4478 per share. This is a positive change from Orion Oyj’s previous dividend of $0.24. The ex-dividend date of this dividend is Monday, April 7th. Orion Oyj’s payout ratio is 24.00%.

Wall Street Analysts Forecast Growth

Separately, Nordea Equity Research lowered shares of Orion Oyj to a “hold” rating in a research report on Tuesday, February 4th.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.